Comment on: no hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria.
Toovey
Stephen
S
D000962:Antimalarials / Q000009:adverse effects*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000009:adverse effects*; D004338:Drug Combinations; D004983:Ethanolamines / Q000009:adverse effects*; D005449:Fluorenes / Q000009:adverse effects*; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D012107:Research Design
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes